Skip to main content
Clinical Trials/NCT04691427
NCT04691427
Recruiting
Early Phase 1

Effectiveness of Vision Therapy in a Virtual Reality Headset

OculoMotor Technologies2 sites in 1 country50 target enrollmentOctober 14, 2021

Overview

Phase
Early Phase 1
Intervention
Not specified
Conditions
Convergence Insufficiency
Sponsor
OculoMotor Technologies
Enrollment
50
Locations
2
Primary Endpoint
Positive Fusional Vergence
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

The purpose of this research study is to see how well the treatment of a participant's eye coordination and/or focusing problems improves eye muscle responses and symptoms of eyestrain. We will use an entertainment device called a virtual reality headset to play a custom-designed video game to find out how well the treatment of binocular vision improves a participant's coordination and/or focusing problem. The virtual reality headset uses eye-trackers to monitor progress in a totally objective manner. Objective testing allows the doctor to determine the results without relying on a participant's ability to answer questions or respond verbally in any way. We will compare the results of a participant before and after playing the video game.

Registry
clinicaltrials.gov
Start Date
October 14, 2021
End Date
September 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 9 years and older
  • CISS score ≥ 16
  • Best-corrected distance visual acuity of 20/25 or better in each eye
  • Random dot stereopsis appreciation of 500 seconds of arc or better
  • Parent or subject understands the protocol and is willing to enroll in the study

Exclusion Criteria

  • Constant strabismus at distance or near
  • Vertical heterophoria ≥ 2 ∆ at distance or near
  • ≥ 2 line interocular difference in best-corrected visual acuity
  • Near point of accommodation \> 20 cm in either eye as measured by push-up method
  • Manifest or latent nystagmus
  • Non-strabismic binocular vision and accommodative disorders associated with known disease of the brain
  • Diseases known to affect accommodation, vergence, or ocular motility such as multiple sclerosis, Graves orbitopathy, myasthenia gravis, diabetes mellitus, Parkinson disease
  • Any ocular or systemic medication known to affect accommodation or vergence such as anti-anxiety agents (e.g., Librium or Valium), anti-arrhythmic agents (e.g., Cifenline, Cibenzoline), anti-cholinergics, bladder spasmolytic drugs (e.g., Propiverine), hydroxychloroquine, chloroquine, phenothiazines (e.g., Compazine, Mellaril, Thorazine), tricyclic antidepressants (e.g., Elavil, Nortriptyline, Tofranil)
  • Inability to comprehend and/or perform any study-related test or procedure

Outcomes

Primary Outcomes

Positive Fusional Vergence

Time Frame: up to 4 weeks post-therapy

Normal range is \>15 Prism Diopters

Near Point of Convergence

Time Frame: up to 4 weeks post-therapy

Normal range is \< 6 cm

Secondary Outcomes

  • Convergence Insufficiency Symptom Survey (CISS)(up to 4 weeks post-therapy)
  • Vision Quality of Life with Time Survey (VisQuaL-T)(up to 4 weeks post-therapy)
  • Core Elements of Gaming Experience Questionnaire(up to 4 weeks post-therapy)

Study Sites (2)

Loading locations...

Similar Trials